Fig. 8: The combinatorial regimen of HOE642, TMZ, and anti-PD-1 antibody increases glioma-bearing mouse survival. | Cell Death & Disease

Fig. 8: The combinatorial regimen of HOE642, TMZ, and anti-PD-1 antibody increases glioma-bearing mouse survival.

From: Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy

Fig. 8

a Experimental protocol and location of data collection. Glioma cells were injected into the right striatum of C57BL6/J mice. Starting 2 d.p.i., mice received vehicle PBS-DMSO (10 ml/kg/day, i.p.), TMZ (2.5 mg/kg/day, i.p.), or T+H combination treatments (2.5+0.5 mg/kg/day, i.p.) for 5 consecutive days. Then mice received either isotype antibody (10 ml/kg/day, i.p.) or anti-PD-1 (10 mg/kg/day, i.p.) at 8, 10, and 12 d.p.i. b Kaplan–Meier survival curve of GL26 tumor-bearing mice (each group n = 5–7). **p < 0.01, ***p < 0.001. c Kaplan–Meier survival curve of SB28-GFP tumor-bearing mice (each group n = 5–7). **p < 0.01, ***p < 0.001

Back to article page